Vitalhub Q2 revenue beats estimates

Overview

• Vitalhub Q2 total revenue up 47% YoY to CAD 23.9 mln, beating estimates, per LSEG data

• Adjusted EBITDA rises 50% YoY to CAD 6.3 mln

• Annual recurring revenue grows 55% YoY to CAD 79.6 mln

Outlook

• Company aims to continue international expansion with current cash and ARR

Result Drivers

• ORGANIC GROWTH - Organic ARR growth contributed C$1.9 mln in Q2, reflecting ongoing expansion efforts

• FOREIGN EXCHANGE - ARR benefited from C$170,566 gain due to favorable foreign exchange rate fluctuations

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Vitalhub Corp is C$15.00, about 9.4% above its August 7 closing price of C$13.59

• The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 46 three months ago

Press Release: ID:nGNX922bmp